M. PACIN, I. MAREMMANI - Vol. 9, March 2003, Issue 1
Testo Bibliografia Summary Indice
Proprietà terapeutiche dei cannabinoidi:
stato dell’arte e implicazioni per la ricerca
Terapeutic properties of cannabinoids: State-of-the-art and research perspectives
1 Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 1995;56:2097-102.
2 Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-87.
3 Beal JE, Olson DO, Morales JO, Belman P, Yangko B, Lefkowitz L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97.
4 Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 1981;21:214-23.
5 Brust JC, Ng SK, Hauser AW, Susser M. Marjuana use and the risk of new onset seizures. Trans Am Clin Climatol Ass 1992;103:176-81.
6 Burnstein S. Prostaglandins and cannabis: IV a biochemical basis for therapeutic application. In: Cohen A, Stillman RC, eds. The therapeutic potential of marijuana. New York: Plenum 1976.
7 Butler JR, Regelson W. Treatment effects of delta-9-THC in an advanced cancer population. In: Cohen A, Stillman RC, eds. The therapeutic potential of marijuana. New York: Plenum 1976.
8 Cabral GA, Pettit DA. Drugs and immunity:cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998;83:116-23.
9 Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21:4175-275.
10 Carriot F, Sasco AJ. Cannabis and cancer. Rev Epidemiol Sante Publique 2000;48:13-20.
11 Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981;47:1746-51.
12 Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. Evaluation of antiemetic effects of delta-9-THC during adjuvant chemotherapy in patients receiving high dose therapy. Ann Int Med 1979;91:825-37.
13 Chen Y, Buck J. Cannabinoids protect cells from oxidative cell death: a receptor independent mechanism. J Pharmacol Exp Ther 2000;293:807-12.
14 Clark WC, Janal MN, Zeidenberg P, Nahas GG. Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharmacol 1981;21:299-310.
15 Clifford DB. THC for tremor in multiple sclerosis. Ann Neurol 1983;13:669-71.
16 Colasanti BK. Review: ocular hypotensive effect of marijuana cannabinoids; correlate of central action or separate phenomenon? J Ocular Pharmacol 1990;6:259-69.
17 Consroe P. Brain cannabinoid systems as target for the treatment of neurological disorders. Neurobiol Dis 1998;5:534-51.
18 Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 1991;40:701-8.
19 Consroe P, Musty R, Rein J, Tillery WPRG. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-8.
20 Consroe P, Snider S. The therapeutic potentual of cannabinoids in neurological disorders. In: Mecholaum R, ed. Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press 1986:21-50.
21 Consroe P, Wood GC, Buchsbaum H. Anticonvulsant Nature of Marijuana Smoking. J Am Med Ass 1975;234:306-7.
22 Consroe PF, Wood GC, Buchsbaum H. Antiepileptic and prophilactic effects of tetrahydrocannabinols in amygdaloid kindled cats. Epilepsia 1975;16:503-10.
23 Cooler P, Gregg JM. Effect of delta-9-THC on intraocular pressure in humans. South Med J 1977;70:954-63.
24 Corcoran ME, McCaughran JAJr, Wade JA. Antiepileptic and prophylactic effect of tetrahydrocannabinols in amygdaloid kindled rats. Epilepsia 1978;19:47-55.
25 Crawford MJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Intern J Clin Pharmacol Biopharm 1979;17:191-6.
26 Cronin CM, Sallan SE, Gelber R, Lucas US, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anti-cancer chemotherapy. J Clin Pharmacol 1981;21:43-52.
27 Cuendet JF, Saprio D, Calanca A, Faggioni R, Ducrey N. Action of delta-9-tetrahydrocannabinol on ophthalmotonus. Ophthalmologica 1976;6:259-69.
28 Cuhna MJ, Carlini EA, Pereira AE, Romos OL, Pimentel C, Gogliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175-85.
29 Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 1988;24:685-9.
30 Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Childhood 1986;61:502-5.
31 De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifullo M, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Nat Acad Sci USA 1998;95:8375-80.
32 Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors
in rat
nodose ganglion. J Neurophysiol 1995;73:907-10.
33 Fattore L, Fratta W. Cannabinoidi ed oppioidi: un percorso neuronale comune? Medicina delle Tossicodipendenze - Italian Journal on Addictions 1999;VII:49-51.
34 Feeney DM. Marihuana and epilepsy: paradoxical anticonvulsant and convulsant effects. Adv Biosci 1978;22-23:643-57.
35 Feeney DM, Spiker M, Weiss GK. Marihuana and epilepsy: activation of symptoms by delta-9-THC. In: Cohen S, Stillman RC, eds. The therapeutic potential of marijuana. New York: Plenum 1977:343-62.
36 Ferri S, Cavicchini E, Romualdi P, Speroni E, Murari G. Possible mediation of catecolaminergic pathways in antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology 1986;89:244-7.
37 Filbert M, Forster JS, Smith CD, Ballough GP. Neuroprotective effects of HU-211 on brain damage from soma-induced seizures. Ann New York Acad Sci 1999;890:504-14.
38 Flom MC, Adams AJ, Jones RT. Marijuana smoking and reduced pressure in human eyes: drug action of epiphenomenon. Investigative Ophthalmol Visual Sci 1975;14:52-5.
39 Friedman H, Klein TW, Newton C, Daaka Y. Marijuana, receptors and immunomodulation. Adv Exp Med Biol 1995;373:103-13.
40 Friedman MA. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis Lung carcinomas. Cancer Biochem Bioph 1977;2:51-4.
41 Frytak S, Moertel CG, O’Fallon J, Rubin J, Creagan ET, O’Connell NJ, et al. delta-9-tetrahydrocannabinol as an antiemetic for patients receiving chemotherapy. A comparison with oral delta-9-tetrahydrocannabinol and prochlorperazine. Cancer 1979;91:825-30.
42 Garb S, Beers AL, Bograd M. Two prolonged studies of tetrahydrocannabinol (THC) in the prevention of vomiting from cancer chemotherapy. IRCS Med Sci 1980;2:203-10.
43 Gong HJr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clin Pharmacol Ther 1984;35:26-32.
44 Gorter R, Seifried M, Volberding P. Dronabinol effects on weight gain in patients with HIV infections. AIDS 1992;6:127.
45 Gorter RW. Management of anorexia-cachexia associated with cancer and HIV infection. Oncology 1991;5:13-7.
46 Gorter RW. Cancer cachexia and cannabinoids. Forsch Komplementarmed 1999;6:21-2.
47 Gralla RJ, Tyson LB, Clark RA, Bordin LA, Kelsen DP, Kalman LB. Antiemetic trials with high-dose metoclopramide: superiority over THC and preservation of efficacy in subsequent chemotherapy courses. Proc Am Soc Clin Oncol 1982;68:58-62.
48 Green K. The ocular effects of cannabinoids. In: Zadunaisky JA, Davison H, eds. Current topics in eye research. New York: Academic Press 1978.
49 Green K. Marihuana in ophtalmology – past, present and future. Ann Ophthalmol 1979;11:203-5.
50 Green K, Kim K, Bowman K. Ocular effects of delta-9-tetrahydrocannabinol. In: Cohen A, Stillman RC, eds. The therapeutic potential of marijuana. New York: Plenum 1976.
51 Green K, Kim K, Wynn H, Shimp RG. Intraocular pressure, organ weights and the chronic use of cannabinoid derivates in rabbits for one year. Exp Eye Res 1977;25:465-71.
52 Green K, McDonald TF. Ocular toxicology of marijuana: an update. J Toxicol-Cut and Ocular Toxicol 1987;6:309-34.
53 Green K, Roth M. Ocular effects of topical administration of delta-9-tetrahydrocannabinol in man. Arch Ophthalmol 1982;100:265-7.
54 Green ST, Nathwani D, Goldberg DJ, Kennedy DH. Nabilone as effective therapy for intractable nausea and vomiting in AIDS. Br J Clin Pharmacol 1989;28:494.
55 Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994;55:324-8.
56 Greenberg I, Kuenhle J, Mendelmson JH, Burnstein JG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology 1976;49:79-84.
57 Grinspoon L, Bakalar JB. Marijuana. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance Abuse: a comprehensive Textbook. Baltimore: Williams and Wilkins 1992:236-46.
58 Haines L, Green W. Marijuana use patterns. Br J Add 1970;65:347.
59 Hampson A, Grimaldi M, Lolik M, Wink D, Rosenthal R, Axelrod J. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Ann NY Acad Sci 2000;899:274-82.
60 Hampson A, Grimaldi M, Lolik M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann NY Acad Sci 2000;89:274-82.
61 Hanigan W, Destree R, Truong XT. The effect of delta-9-THC on human spasticity. Am Soc Clin Pharmacol Ther 1986;198:148-56.
62 Harris LS. Analgesic and antitumor potential of the cannabinoids. In: Cohen A, Stillman RC, eds. The therapeutic potential of marijuana. New York: Plenum 1976:124-37.
63 Hepler RS, Frank IM, Petrus R. Ocular effects of marihuana smoking. In: Braude DW, Szara S, eds. Marihuana in Oftalmology. New York: Raven Press 1976:815-24.
64 Hepler RS, Frank IR. Marihuana smoking and intraocular pressure. JAMA 1971;217:1392.
65 Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New England J Med 1979;300:1295-7.
66 Hernandez MJ, Martinez F, Blair HT, Miller WC. Airway response to inhaled histamine in asymptomatic long-term marijuana smokers. J All Clin Immunol 1981;67:153-5.
67 Hill SV, Schwin R, Goodwin DW, Powell BJ. Marijuana and pain. J Pharmacol Exp Ther 1974;188:415-8.
68 Hollister LE. Hunger and appetite after single doses of marijuana,alcohol and dextroamphetamine. Clin Pharmacol Ther 1971;12:44-9.
69 Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981;21:320-6.
70 Jay WM, Green K. Multiple drop study of topically applied 1% delta-9-tetrahydrocannabinol in human eyes. Arch Ophthalmol 1983;101:591-3.
71 Johnson DD, McNeill JR, Crawford RD, Wilcox WC. Epileptiform seizures in domestic fowl. The anticonvulsant activity of delta-9-tetrahydrocannabinol. Canadian J Physiol Pharmacol 1975;53:1007-13.
72 Karler R, Turkanis SA. The antiepileptic potential of the cannabinoids. In: Cohen A, Stillman RC, eds. The therapeutic potential of marijuana. New York: Plenum 1976:236-51.
73 Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. J Clin Pharmacol 1981;21:437-48.
74 Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J, Coulson AH, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1 positive individuals. JAMA 1989;26:3424-9.
75 Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol 1998;83:102-15.
76 Kuttner MH. Evaluation of the use of both marijuana and THC in cancer patients for the relief of nausea and vomiting associated with cancer chemotherapy after failure of conventional antiemetic therapy: efficacy and toxicity.Report for the Composite State Board of Medical Examiners. Atlanta: Georgia Dept. of Health 1984.
77 Lewis IH, Campbell DN, Barrowcliffe MP. Effect of nabilone on nausea and vomiting after total abdominal hystetectomy. Br J Anaesth 1994;73:244-6.
78 Libman E, Stern MH. The effects of delta-9-tetrahydrocannabinol on cutaneous sensitivity and its relation to personality. Personality, individuality and differences 1985;6:169-74.
79 Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periacqueductal gray involvement. J Pharmacol Exp Ther 1996;276:583-93.
80 Lichtmann AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal alfa-noradrenergic mechanism. Brain Res 1991;559:309-14.
81 Lichtmann AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991;258:517-23.
82 Long A, Mioduzeuski J, Natale R. A randomized double-blind crossover comparison of the antiemetic activity of levonantradol and prochlorperazine. Proc Am Soc Clin Oncol 1982;1:57.
83 Lucas VSJr, Lazslo J. Delta-9-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 1980;243:1241-3.
84 Lucraft HH, Palmer MK. Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 1982;33:621-2.
85 Malec J, Harvey RF, Cayner JJ. Cannabis effect on spasticity in spinal cord Injury. Arch Phys Med Rehab 1982;63:116-8.
86 Martin BR, Lichtman AH. Cannabinoid transmission and pain perception. Neurobiol Dis 1998;5:447-61.
87 Martin P, Consroe P. Cannabinoid induced behavioral convulsions in rabbits. Sci 1976;194:965-7.
88 Martin WJ, Hohmann AJ, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 1996;16:6601-11.
89 Masset D, Bourdon JH, Arditti-Djiane J, Jouglard J. Impact of delta-9-tetrahydrocannabinol and its metabolytes on the immune system. Acta Clinica Belgica 1999;1(Suppl):39-43.
90 Mattes RD, Engelman K, Shaw LM, Elsohly MA. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994;49:187-95.
91 Maurer M, Henn V, Dittrich A, Hoffman A. Delta-9-THC shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 1990;240:1-4.
92 McCarthy LE, Borison HL. Antiemetic activity of nabilone,a cannabinol derivative,reversed by naloxone in awake rats. Pharmacology 1977;19:230.
93 Mechoulam R, Carlini EA. Towards drugs derived from cannabis. Naturwissenschaften 1978;65:174-9.
94 Meinck HM, Schlone FW, Conrad B. Effects of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989;236:120-2.
95 Merritt J, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effects of marihuana on intraocular blood pressure in glaucoma. Ophthalmology 1980;87:222-8.
96 Merritt JC. Glaucoma, hypertension and marijuana. J Nat Med Ass 1982;74:715-6.
97 Merritt JC. Glaucoma, hypertension, and marijuana. J Nat Med Ass 1982;74:715-6.
98 Merritt JC. Topical delta-9-tetrahydrocannabinol as a potential antiglaucoma agent. Glaucoma 1982;4:253-5.
99 Miller AS, Walker JM. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur J Pharmacol 1995;279:179-85.
100 Musty RE, Lindey CJ, Carlini EA. 6-Hydroxidopamine and the aggressive behavior induced by marihuana in REM sleep deprived rats. Psychopharmacology 1976;48:175-9.
101 Nagy CM, Furnas BE, Einhorn LH, Bond WH. Nabilone antiemetic crossover study in cancer chemotherapy patients. Proc Am Ass Cancer Res 1978;19:30-7.
102 Nelson K, Walsh D, Deeter P, Sheehan F. A phase-II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia (Review). J Palliative Care 1994;10:14-8.
103 Newell FW, Stark P, Jay WM, Schanzlin DJ. Nabilone: a pressure-reducing synthtetic cannabinoid in open-angle glaucoma. Ophthalmology 1979;86:156-60.
104 Ng SKC, Brust JCM, Hauser WA, Susser M. Illicit drug use and the risk of new-onset seizures. Am J Epidemiol 1990;132:47-57.
105 NIDA. Marijuana research findings: 198. Monograph 31. Rockville, Maryland: NIDA 1980.
106 Niiranen A, Mattson K. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol 1987;10:325-9.
107 Notcutt W, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharm Sci 1997;3:551-5.
108 Noyes R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84-9.
109 Noyes R, Brunk SF, Baram DA, Canter AC. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Psychopharmacol 1975;15:139-43.
110 Orr LE, McKernan JF. Antiemetic effect of delta-9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 1981;21:76-80.
111 Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Int Med 1980;140:1431-3.
112 Passatore M, Casoni RP, Chiarotti M, Guisti GV. Effect of THC on the supramaximal stimulation of the mouse sciatic nerve. Acta Medica Roma 1975;13:427-31.
113 Perez-Reyes M, Wagner D, Wall ME, Davis KH. Intravenous administration of cannabinoids and intraocular pressure. In: Braude MC, Szara S, eds. The pharmacology of marihuana. New York: Rave Press 1976:147-58.
114 Perez-Reyes M, Wingfield M. Cannabidiol and electroencephalographic epileptic activity. Letter. JAMA 1974;230:1635.
115 Petro DJ. Marijuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980;221:81.
116 Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-THC. J Clin Pharmacol 1981;21(Suppl).
117 Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986;17:285-8.
118 Porcella A, Gessa GL, Pani L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body. Brain Res Molecular Brain Res 1998;58:240-5.
119 Pugh G, Abood ME, Welch SP. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta-9-THC in the spinal cord. Brain Res 1995;689:157-8.
120 Pugh G, Smith PB, Dombrowski DS, Welch SP. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996:608-16.
121 Rachelefsky GS, Opelz G, Mickey MR, Lessin P, Kiuchi M, Silverstein MU, et al. Intact humoral and cell-mediated immunity in chronic marijuana smoking. J Allergy Clin Immunol 1976;58:483-90.
122 Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Clin Pharmacol Ther 1977;21:26-33.
123 Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. New England J Med 1980;302:135-8.
124 Sallan SE, Zinberg NE, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New England J Med 1975;293:795-7.
125 Sandyk R, Awerbuch G. Marijuana and Tourette’s syndrome. J Clin Psychopharmacol 1988;8:444-5.
126 Sandyk R, Snider SR, Consroe P, Elias SM. Cannabidiol in dystonic movement disorders. Psychiatr Res 1986;18:291.
127 Sanudo-Pena MC, Patrick SL, Patrick RL, Walker JM. Effects of intranigral cannabinoids on rotational behavior in rats: interaction with the dopaminergic system. Neuroscience Letters 1996;206:21-4.
128 Sanudo-Pena MC, Walker JM. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 1997;77:1635-8.
129 Sanudo-Pena MC, Walker JM. Effects of intrastriatal cannabinoids on rotational behavior in rats; interaction with the dopaminergic system. Synapse 1998;30:221-6.
130 Shannon HE, Zinberg NE, Frei E. Lack of antiemetic effects of delta-9-tetrahydrocannabinol in apomorphine induced emesis in the dog. Life Sci 1978;23:49-53.
131 Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996;16:4322-34.
132 Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989;249:444-9.
133 Stambaugh JE, McAdams J, Vreeland F. A phase II randomized trial of the antiemetic activity of levonantradol in cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 1982;62:146-53.
134 Staquet M, Gantt C, Machin D. Effect of a nitrogen analogue of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978;23:397-401.
135 Steele N, Gralla RJ, Braun DW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219-25.
136 Sweet DL, Miller NJ, Weddington W, Senay E, Sushelsky L. Delta-9-tetrahydrocannabinol as an entiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 1981;21:70-5.
137 Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanisms. Science 1997;276:2048-50.
138 Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common m1 opioid receptor mechanism. Science 1997;276:2048-50.
139 Tart CT. Marijuana intoxication: common experiences. Nature 1970;226:701-5.
140 Tashkin BJ, Shapiro DP, Frank IM. Acute effects of smoked marijuana and oral delta-9-THC on specific airway conductance in asthmatic subjects. Am Rev Respir Dis 1974;109:420-8.
141 Tashkin DP, Reiss S, Shapiro BJ, Calverese BM, Olsen JL, Lodge JW. Bronchial effects of aerosolized delta-9-THC in healthy and asthmatic subjects. Am Rev Resp Dis 1977;115:57-65.
142 Tiedeman JS, Shields MB, Weber PA, Croz JW, Cocchetto DM, Harris WA, et al. Effect of synthethic cannabinoids on elevated intraocular pressure. Ophthalmology 1981;88:117-21.
143 Ungerleider JY, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 1982;50:636-45.
144 Vachon L, Robins A, Gaensler EA. Airways response to aeroslized delta-9-tetrahydrocannabinol: preliminary report. Chest 1976;70:444-8.
145 Vaysse PJ-J, Gardener EL, Zukin RS. Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther 1987;241:534-9.
146 Vincent BJ, McQuiston DJ, Einhorn LH, Nagy MC, Brames MJ. Review of cannabinoids and their antiemetic effectiveness. Drugs 1983;25:52-62.
147 Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Ger Psychiatry 1997;12:913-9.
148 White A, Munson A, Carchman R. Effects of delta-9-THC in Lewis lung adenocarcinoma cells in tissue culture. J Nat Cancer Institute 1976;56:155-8.
149 Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 1977;31:720-3.
150 Wilson RS, May EL. 9-nor-8-tetrahydrocannabinol:a cannabinid of metabolic interest. J Med Chem 1974;17:475-6.
151 Wilson RS, May EL. Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs. J Med Chem 1975;18:700-3.
152 Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacol 1991;104:260-4.